Preparation and in vivo study of dry powder microspheres for nasal immunization

References

• Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. (2005). Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev, 57: 411–430.
   PubMed Web of Science ®Google Scholar
• Amin M, Jaafari MR, Tafaghodi M. (2009). Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids Surf B Biointerfaces, 74: 225–229.
   PubMed Web of Science ®Google Scholar
• Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, Chatfield S, Roberts M. (2000). Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun, 68: 5764–5770.
   PubMed Web of Science ®Google Scholar
• Bjork E, Edman P. (1990). Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int J Pharm, 62(2–3): 187–192.
   Google Scholar
• Carr RM, Lolachi CM, Albaran RG, Ridley DM, Montgomery PC, O’Sullivan NL. (1996). Nasal-associated lymphoid tissue is an inductive site for rat tear IgA antibody responses. Immunol Invest, 25: 387–396.
   PubMed Web of Science ®Google Scholar
• Chandler SG, Ilium L, Thomas NW. (1991). Nasal absorption in rats. II. Effect of enhancers on insulin absorption and nasal histology. Int J Pharm, 76(1–2): 61–70.
   Google Scholar
• Cornaz A-L, De Ascentis A, Colombo P, Buri P. (1996). In vitro characteristics of nicotine microspheres for transnasal delivery. Int J Pharm, 129(1–2): 175–183.
   Google Scholar
• Csaba N, Garcia-Fuentes M, Alonso MJ. (2009). Nanoparticles for nasal vaccination. Adv Drug Deliv Rev, 61: 140–157.
   PubMed Web of Science ®Google Scholar
• Ellis JA, West KH, Waldner C, Rhodes C. (2005). Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves. Can Vet J, 46: 155–162.
   PubMed Web of Science ®Google Scholar
• Eyles JE, Williamson ED, Alpar HO. (1999). Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. Int J Pharm, 189: 75–79.
   PubMed Web of Science ®Google Scholar
• Garmise RJ, Staats HF, Hickey AJ. (2007). Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech, 8: E81.
   PubMed Web of Science ®Google Scholar
• Gill IJ, Fisher AN, Farraj N, Pitt CG, Davis SS, Illum L. (1998). Intranasal absorption of granulocyte-colony stimulating factor (G-CSF) from powder formulations, in sheep. Eur J Pharm Sci, 6: 1–10.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Siber GR. (1995). Adjuvants for human vaccines—current status, problems and future prospects. Vaccine, 13: 1263–1276.
   PubMed Web of Science ®Google Scholar
• Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W. (2009). Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release: 140(2):126–133.
   PubMed Web of Science ®Google Scholar
• Illum L, Jørgensen H, Bisgaard H, Krogsgaard O, Rossing N. (1998). Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm, 39(3): 189–199.
   Google Scholar
• Illum L, Fisher AN, Jabbal-Gill I, Davis SS. (2001). Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm, 222: 109–119.
   PubMed Web of Science ®Google Scholar
• Illum L, Farraj NF, Davis SS, Johansen BR, O’Hagan DT. (1990). Investigation of the nasal absorption of biosynthetic human growth hormone in sheep—use of a bioadhesive microsphere delivery system. Int J Pharm, 63(3): 207–211.
   Google Scholar
• Ishii M, Kojima N. (2009). Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization. Glycoconj J. DOI 10.1007/s10719-009-9263-8.
   PubMed Web of Science ®Google Scholar
• Jain AK, Khar RK, Ahmed FJ, Diwan PV. (2008). Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm, 69: 426–435.
   PubMed Web of Science ®Google Scholar
• Jiang HL, Kang ML, Quan JS, Kang SG, Akaike T, Yoo HS, Cho CS. (2008). The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials, 29: 1931–1939.
   PubMed Web of Science ®Google Scholar
• Johansen P, Men Y, Merkle HP, Gander B. (2000). Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm, 50: 129–146.
   PubMed Web of Science ®Google Scholar
• Kayamuro H, Abe Y, Yoshioka Y, Katayama K, Nomura T, Yoshida T, Yamashita K, Yoshikawa T, Kawai Y, Mayumi T, Hiroi T, Itoh N, Nagano K, Kamada H, Tsunoda S, Tsutsumi Y. (2009). The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials, 30: 5869–5876.
   PubMed Web of Science ®Google Scholar
• Kensil CR, Wu JY, Soltysik S. (1995). Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol, 6: 525–541.
   PubMedGoogle Scholar
• Kensil CR. (1996). Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst, 13: 1–55.
   PubMed Web of Science ®Google Scholar
• Lemoine D, Wauters F, Bouchend’homme S, Préat V. (1998). Preparation and characterization of alginate microspheres containing a model antigen. Int J Pharm, 176(1): 9–19.
   Google Scholar
• Makidon PE, Nigavekar SS, Bielinska AU, Mank N, Shetty AM, Suman J, Knowlton J, Myc A, Rook T, Baker JR. (2009). Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines. J Aerosol Med Pulm Drug Deliv.
   Web of Science ®Google Scholar
• Nishino M, Mizuno D, Kimoto T, Shinahara W, Fukuta A, Takei T, Sumida K, Kitamura S, Shiota H, Kido H. (2009). Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs. Vaccine, 27: 5620–5627.
   PubMed Web of Science ®Google Scholar
• O’agan DT. (1996). The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat, 189 (Pt 3): 477–482.
   PubMedGoogle Scholar
• O’Hagan DT, Rafferty D, Wharton S, Illum L. (1993). Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine, 11: 660–664.
   PubMed Web of Science ®Google Scholar
• Oechslein CR, Fricker G, Kissel T. (1996). Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems. Int J Pharm, 139(1–2): 25–32.
   Google Scholar
• Payne JM, Sansom BF, Garner RJ, Thomson AR, Miles BJ. (1960). Uptake of small resin particles (1-5 microns diameter) by the alimentary canal of the calf. Nature, 188: 586–587.
   PubMed Web of Science ®Google Scholar
• Pereswetoff-Morath L. (1998). Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev, 29: 185–194.
   PubMed Web of Science ®Google Scholar
• Pereswetoff-Morath L, Edman P. (1995). Dextran microspheres as a potential nasal drug delivery system for insulin—in vitro and in vivo properties. Int J Pharm, 124(1): 37–44.
   Google Scholar
• Pereswetoff-Morath L, Edman P. (1996). Immunological consequences of nasal drug delivery in dextran microspheres and ethyl(hydroxyethyl)cellulose in rats. Int J Pharm, 128(1–2): 23–28.
   Google Scholar
• Pickering RJ, Smith SD, Strugnell RA, Wesselingh SL, Webster DE. (2006). Crude saponins improve the immune response to an oral plant-made measles vaccine. Vaccine, 24: 144–150.
   PubMed Web of Science ®Google Scholar
• Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H. (2001). Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol, 83: 93–105.
   PubMed Web of Science ®Google Scholar
• Rydell N, Sjöholm I. (2004). Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine, 22: 1265–1274.
   PubMed Web of Science ®Google Scholar
• Rydell N, Sjöholm I. (2005). Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin. Vaccine, 23: 2775–2783.
   PubMed Web of Science ®Google Scholar
• Ryden L, Edman P. (1982). Effect of polymers and microspheres on the nasal absorption of insulin in rats. Int J Pharm, 83(1–3): 1–10.
   Google Scholar
• Sajadi Tabassi SA, Tafaghodi M, Jaafari MR. (2008). Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm, 360: 12–17.
   PubMed Web of Science ®Google Scholar
• Sanders MT, Deliyannis G, Pearse MJ, McNamara MK, Brown LE. (2009). Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine, 27: 2475–2482.
   PubMed Web of Science ®Google Scholar
• Skene CD, Sutton P. (2006). Saponin-adjuvanted particulate vaccines for clinical use. Methods, 40: 53–59.
   PubMed Web of Science ®Google Scholar
• Song X, Hu S. (2009). Adjuvant activities of saponins from traditional Chinese medicinal herbs. Vaccine, 27: 4883–4890.
   PubMed Web of Science ®Google Scholar
• Stertman L, Lundgren E, Sjöholm I. (2006). Starch microparticles as a vaccine adjuvant: only uptake in Peyer’s patches decides the profile of the immune response. Vaccine, 24: 3661–3668.
   PubMed Web of Science ®Google Scholar
• Stertman L, Strindelius L, Sjöholm I. (2004). Starch microparticles as an adjuvant in immunisation: effect of route of administration on the immune response in mice. Vaccine, 22: 2863–2872.
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. (2009). Advances in saponin-based adjuvants. Vaccine, 27: 1787–1796.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Abolghasem Sajadi Tabassi S, Jaafari MR, Zakavi SR, Momen-Nejad M. (2004). Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. Int J Pharm, 280: 125–135.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Jaafari MR, Sajadi Tabassi SA. (2006). Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur J Pharm Biopharm, 64: 138–145.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Sajadi Tabassi SA, Jaafari MR. (2006). Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm, 319: 37–43.
   PubMed Web of Science ®Google Scholar
• Ugwoke MI, Agu RU, Verbeke N, Kinget R. (2005). Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev, 57: 1640–1665.
   PubMed Web of Science ®Google Scholar